In the last decades, evidence suggesting the direct or indirect involvement of B cells on
multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on …

Autoimmune diseases are characterized by the recognition of self‐antigens by the immune
system, which leads to inflammation and tissue damage. B cells are directly and indirectly …

Following a similar report on multiple myeloma, Ghione and colleagues report the expected
observation that patients with non-Hodgkin lymphoma (NHL) receiving anti-B cell therapies …

Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-
19, is essential to help control the infection. The neutralization activity of plasma from …

Background The chimeric anti-CD20 monoclonal antibody rituximab is effective in steroid-
dependent and calcineurin inhibitor–dependent forms of nephrotic syndrome, but many …

In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …

Background B-cell depletion with rituximab induces sustained remission in children with
steroid-dependent or frequently relapsing nephrotic syndrome. However, most patients …

Background Anti-CD20 antibody therapy may be associated with an increased risk of
infections. We therefore investigated risk factors for infection in patients with demyelinating …

When first introduced, rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, brought
about an alternative therapeutic paradigm for primary membranous nephropathy (PMN) …

Background Rituximab is a B-cell depleting agent used in B-cell malignancies and
autoimmune diseases. A subset of adult patients may develop prolonged and symptomatic …